Optimization of Active Molecules Towards a Pre-Clinical in Vivo Proof of Mechanism of ARSACS Phenotype Reversal – Dr. Michel Bouvier

To develop small molecules that reverse the cellular phenotype of ARSACS into a drug that would stop the progression of the disease and/or lead to clinical improvement. Grant: $160,000 Contact Dr.Michel Bouvier, Institute for Research in Immunology and Cancer (IRIC) IRIC | Université de Montréal C.P. 6128, succursale Centre-ville, Montréal (Québec) H3C 3J7 Tel: (514)-343-6319 ; Email: michel.bouvier@umontreal.ca